PXD017919

PXD017919 is an original dataset announced via ProteomeXchange.

Title	Differential proteomics analysis on plasma from anlotinib-treated advanced non-small cell lung cancer patients
Description	Anlotinib has been demonstrated to be effective in advanced non-small cell lung cancer (NSCLC) patients. DNA-seq- and RNA-seq-based anlotinib molecular mechanism and biomarker screening have been introduced in previous studies. The underlying value of proteomics for anlotinib study is still unclear. In this study, 70 plasma samples were selected from 28 anlotinib-treated NSCLC patients (including 14 responders and 14 non-responders). LC-MS/MS analysis was performed on those samples with different time points including baseline, best response and progression disease. Bioinformatics analysis was performed to understand the underlying value of those differential proteins. Proteomics analysis suggested the differential proteins from responders after anlotinib administration potential play a role in the molecular mechanism characterization and biomarker screening. The differential proteins between responders and non-responders at baseline mainly contribute to biomarker screening. Integrative analysis indicated 43 proteins could be used as underlying biomarkers for clinical practice. Lastly, we selected ARHGDIB and demonstrated that it has some predictive value for anlotinib. Collectively, this study not only offered the first insight that the proteomic technology potentially be used for anlotinib molecular mechanism characterization, but also provided a basis for anlotinb biomarker screening via proteomics in the future.
HostingRepository	iProX
AnnounceDate	2020-03-05
AnnouncementXML	Submission_2023-08-27_20:58:07.650.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	June Lu
SpeciesList	scientific name: Homo sapiens; NCBI TaxID: 9606;
ModificationList	TMT6plex reporter+balance reagent acylated residue
Instrument	Q Exactive Plus

Revision	Datetime	Status	ChangeLog Entry
0	2020-03-06 01:23:14	ID requested
1	2020-03-06 01:25:14	announced
⏵ 2	2023-08-27 20:58:11	announced	2023-08-28: Update publication information.

Lu J, Zhang W, Yu K, Zhang L, Lou Y, Gu P, Nie W, Qian J, Xu J, Wang H, Zhong H, Han B, Screening anlotinib responders via blood-based proteomics in non-small cell lung cancer. FASEB J, 36(8):e22465(2022) [pubmed]

submitter keyword: Proteomics, Anlotinib, Biomarker, Non-small cell lung cancer, liquid biopsy

Baohui Han
contact affiliation	Shanghai Jiao Tong University Affiliated Chest Hospital
contact email	18930858216@163.com
lab head
June Lu
contact affiliation	Shanghai Jiao Tong University Affiliated Chest Hospital
contact email	lujun512@yahoo.com
dataset submitter

iProX dataset URI